Vericel Co. (NASDAQ:VCEL) CEO Sells $1,217,381.76 in Stock

Vericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo sold 26,592 shares of Vericel stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $45.78, for a total value of $1,217,381.76. Following the completion of the transaction, the chief executive officer now owns 259,997 shares in the company, valued at $11,902,662.66. The trade was a 9.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Vericel Stock Performance

Shares of VCEL stock traded up $0.09 during trading on Friday, hitting $45.48. 255,445 shares of the company were exchanged, compared to its average volume of 379,431. The business’s 50-day simple moving average is $55.83 and its 200 day simple moving average is $51.89. Vericel Co. has a twelve month low of $39.12 and a twelve month high of $63.00. The firm has a market capitalization of $2.27 billion, a price-to-earnings ratio of 758.04 and a beta of 1.78.

Wall Street Analysts Forecast Growth

VCEL has been the subject of a number of recent analyst reports. BTIG Research increased their price target on Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Stephens reiterated an “overweight” rating and issued a $65.00 target price on shares of Vericel in a report on Wednesday, January 15th. HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of Vericel in a research report on Friday, February 28th. StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research report on Saturday, March 8th. Finally, Canaccord Genuity Group lifted their price objective on shares of Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $62.29.

Institutional Investors Weigh In On Vericel

Institutional investors have recently modified their holdings of the stock. Arcadia Investment Management Corp MI acquired a new position in shares of Vericel in the fourth quarter worth $48,000. GF Fund Management CO. LTD. purchased a new position in Vericel in the fourth quarter valued at about $57,000. Farther Finance Advisors LLC increased its position in Vericel by 48.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 405 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in shares of Vericel by 511.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 1,058 shares in the last quarter. Finally, Meeder Asset Management Inc. acquired a new stake in shares of Vericel during the 3rd quarter valued at about $92,000.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.